Glukoza Viaflo Baxter

Glukoza Viaflo Baxter is an intravenous solution containing glucose as the active ingredient. It is supplied as a parenteral carbohydrate solution for use in clinical settings. The product is marketed in the European Union and is available by prescription only. It is designed to provide a rapid source of energy and to support fluid and electrolyte balance when administered intravenously.

Glukoza Viaflo Baxter is indicated for several clinical situations where rapid carbohydrate delivery and fluid replacement are required.

- Treatment of acute hypoglycemia in hospital settings. - Fluid and electrolyte replacement during dehydration or postoperative care. - Component of parenteral nutrition regimens for patients unable to eat orally. - Intra‑operative glucose support to maintain blood sugar levels. - Management of metabolic needs in critically ill patients. - Support for patients with impaired oral intake or gastrointestinal dysfunction.

Glukoza Viaflo Baxter may be associated with a range of adverse reactions, most of which are related to its glucose content and intravenous administration.

Common: - Transient hyperglycemia or elevated blood glucose levels. - Local irritation or phlebitis at the infusion site. - Mild nausea or gastrointestinal discomfort. - Electrolyte disturbances such as mild hyponatremia. - Fluid overload in patients with limited cardiac reserve.

Serious: - Severe hyperglycemia requiring medical intervention. - Anaphylactic or severe allergic reactions. - Metabolic acidosis in susceptible individuals. - Cardiac arrhythmias secondary to electrolyte shifts. - Pulmonary edema from excessive fluid administration.

When using Glukoza Viaflo Baxter, clinicians should observe several safety considerations to minimize risk.

- Monitor blood glucose levels frequently, especially in diabetic patients. - Assess fluid status and cardiac function to avoid volume overload. - Adjust infusion rates in patients with renal or hepatic impairment. - Review electrolyte balance regularly during prolonged therapy. - Use with caution in pregnancy and lactation, as safety data are limited. - Pediatric administration should be performed under specialist supervision. - Ensure proper aseptic technique to reduce infection risk at the infusion site.

Glukoza Viaflo Baxter can interact with other medications or therapies that affect glucose metabolism or fluid balance.

Avoid: - Simultaneous high‑dose insulin therapy without dose adjustment, as it may precipitate severe hypoglycemia. - Co‑administration with other hyperglycemic agents that could cause uncontrolled hyperglycemia.

Use with caution: - Diuretics, which may exacerbate electrolyte disturbances. - Corticosteroids, which can increase blood glucose levels. - Beta‑adrenergic agonists, which may raise glucose concentrations. - Other intravenous fluids, to prevent cumulative fluid overload. - Electrolyte solutions, to maintain appropriate serum electrolyte concentrations.